Lightspeed, Klausner back Stanford cell therapy spinout Orca in new $192M round

Orca Bio is developing allogeneic cell therapies designed to reduce toxicity

With the completion of a new $192 million series D round, Stanford spinout Orca Bio has now raised nearly $300 million to develop and manufacture allogeneic cell therapies that use controlled formulations designed to reduce toxicity compared with traditional bone marrow transplants.

Orca Biosystems Inc. has been operating quietly since its 2016 establishment to build upon work done in the academic setting by the three co-founders on its management team. The team worked with Stanford University professor Irv Weissman, who is director of the university’s Institute of Stem Cell Biology and Regenerative Medicine

Read the full 928 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE